Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Real Time Quote from BATS)

$250.75 USD

250.75
1,428,787

-9.48 (-3.64%)

Updated Aug 26, 2026 02:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (157 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

by Zacks Equity Research

Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.

Kinjel Shah headshot

Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III

by Kinjel Shah

FDA approves AstraZeneca's (AZN) Voydeya (danicopan) in the United States as add on therapy to its other C5 inhibitors. Merck (MRK) begins a phase III study on its oral KRAS G12C inhibitor candidate.

Zacks Equity Research

Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate

by Zacks Equity Research

Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.

Zacks Equity Research

Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study

by Zacks Equity Research

Axsome's (AXSM) phase III ENGAGE study is set to evaluate the efficacy and safety of solriamfetol for the treatment of binge eating disorder in adults.

Zacks Equity Research

Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal

by Zacks Equity Research

Data from a late-stage study shows that a five-week treatment with Axsome's (AXSM) experimental narcolepsy drug reduced weekly cataplexy attacks by 83%, compared to 66% for placebo.

Zacks Equity Research

Axsome (AXSM) Begins Dosing in Depression Study on Sunosi

by Zacks Equity Research

Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.

Zacks Equity Research

Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates

by Zacks Equity Research

Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.